(Mark One)
[ X ] Quarterly report pursuant to Section 13 or $15(\mathrm{~d})$ of the Securities Exchange Act of 1934 for the quarterly period ended March 31, 1997; or
[ ] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to
$\qquad$ -.

Commission File Number:

FORENSIC TECHNOLOGIES INTERNATIONAL CORPORATION
(Exact Name of Registrant as Specified in its Charter)

## MARYLAND

(State or other Jurisdiction of Incorporation or Organization)

52-1261113
(I.R.S. Employer Identification No.)

2021 Research Drive, Annapolis, Maryland (Address of Principal Executive Offices)
(410) 224-8770
(Registrant's Telephone Number, Including Area Code)

> (Former name, former address and former fiscal year, if changed since last report)

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or $15(d)$ of the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
[ X ] Yes [ ] No

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date.

## Class

Common Stock, par value
\$.01 per share

Outstanding at May 14, 1997
$4,526,912$ shares

FORENSIC TECHNOLOGIES INTERNATIONAL CORPORATION INDEX


Forensic Technologies International Corporation and Subsidiary

## Consolidated Balance Sheets (Unaudited)

| DECEMBER 31, | MARCH 31, |
| :---: | :---: |
| 1996 | 1997 |

ASSETS
Current assets:
$\quad$ Cash and cash equivalents
Accounts receivable, less allowance of $\$ 250,877$ in 1996 and
$\$ 243,790$ in 1997
Unbilled receivables, less allowance of $\$ 125,439$ in 1996 and
$\quad \$ 162,526$ in 1997
Inventory
Income taxes receivable
Deferred income taxes
Prepaid expenses
Total current assets
Property and equipment:
Buildings
Furniture and equipment

Leasehold improvements

Accumulated depreciation and amortization

Other assets

| $\$$ | $5,893,897$ | $5,713,454$ |
| ---: | ---: | ---: |
| $6,296,599$ | $6,708,425$ |  |
| $3,006,953$ | $3,462,336$ |  |
| 332,828 | 332,828 |  |
| 111,471 | - |  |
| 185,926 | 185,926 |  |
| 418,654 | 487,601 |  |


| 3 |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |  |  |

16,246,328 16,890,570

| 411, 241 | 411, 241 |
| :---: | :---: |
| 8,455,373 | 9,150,921 |
| 863,821 | 1,127,302 |
| 9,730,435 | 10,689,464 |
| $(5,624,060)$ | $(5,926,078)$ |
| 4,106,375 | 4,763,386 |
| 515,722 | 522,469 |

```
DECEMBER 31, MARCH 31,
    1996
    1 9 9 7
```


## LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
Accounts payable and accrued expenses
Accrued compensation expense
Income taxes payable
Current portion of capital lease obligations
Advances from clients
Other current liabilities
Total current liabilities

Long-term debt and capital lease obligations, less current portion Deferred income taxes
Commitments and contingent liabilities
Stockholders' equity:
Preferred stock, $\$ .01$ par value; 4,000,000 shares authorized, none outstanding
Common stock, \$.01 par value:
Authorized shares - 16,000,000 shares issued and outstanding 4,516,912 in 1996, and 4,526,912 in 1997
Additional paid-in capital
Retained earnings

Total stockholders' equity

Total liabilities and stockholders' equity


See Accompanying Notes.

## Forensic Technologies International Corporation and Subsidiary

Consolidated Statements of Operations (Unaudited)

THREE MONTHS ENDED MARCH 31
1996
1997
(Restated Note 1)

| Revenues | \$ | 6, 965,654 | \$ | 9,539,549 |
| :---: | :---: | :---: | :---: | :---: |
| Direct cost of revenues |  | 3,750,970 |  | 5,161, 672 |
| Selling, general and administrative expenses |  | 2,626,903 |  | 3,349,544 |
| Total costs and expenses |  | 6,377,873 |  | 8,511,216 |
| Income from operations |  | 587,781 |  | 1, 028, 333 |
| Other income (expenses): |  |  |  |  |
| Interest and other income |  | 32,290 |  | 75,680 |
| Interest expense |  | $(80,433)$ |  | $(19,971)$ |
|  |  | $(48,143)$ |  | 55,709 |
| Income before income taxes |  | 539,638 |  | 1,084, 042 |
| Income taxes |  | 235,212 |  | 444,457 |
| Net income | \$ | 304,426 | \$ | 639,585 |
| Earnings Per Share Data: <br> Net income per common and common equivalent share: |  |  |  |  |
|  |  | \$0.14 |  | \$0.14 |
| Net income per common share, assuming full dilution: |  | \$0.10 |  | \$0.14 |

See Accompanying Notes.

## Forensic Technologies International Corporation and Subsidiary

```
Consolidated Statements of Cash Flows (Unaudited)
```


## OPERATING ACTIVITIES

| Net income | \$ | 304,426 | \$ | 639,585 |
| :---: | :---: | :---: | :---: | :---: |
| Adjustment to reconcile net income to net cash provided by (used |  |  |  |  |
| in) operating activities: |  |  |  |  |
| provided by (used in) operating activities: |  |  |  |  |
| Depreciation |  | 165,850 |  | 278,317 |
| Amortization |  | 15,394 |  | 32,838 |
| Non-cash compensation |  | 10,841 |  | - |
| Provision for doubtful accounts |  | 45,489 |  | 30,000 |
| Loss on disposal of discontinued Annapplix division |  | $(471,869)$ |  | - |
| Changes in operating assets and liabilities: |  |  |  |  |
| Accounts receivable |  | $(12,058)$ |  | $(404,739)$ |
| Unbilled receivables |  | $(764,866)$ |  | $(492,470)$ |
| Prepaid expenses |  | $(9,638)$ |  | $(68,947)$ |
| Accounts payable |  | 113,842 |  | $(36,540)$ |
| Accrued compensation expense |  | 328,328 |  | 255,390 |
| Income taxes payable |  | 202,888 |  | 425,777 |
| Deferred revenue |  | $(83,333)$ |  | - |
| Advances from clients |  | - |  | $(42,297)$ |
| Other current liabilities |  | 122,715 |  | (11, 063 ) |
| Net cash provided by (used in) operating activities |  | $(31,991)$ |  | 605,851 |
| INVESTING ACTIVITIES |  |  |  |  |
| Purchase of property and equipment |  | $(364,482)$ |  | $(751,404)$ |
| Change in other assets |  | $(4,057)$ |  | $(8,001)$ |
| Net cash used in investing activities |  | $(368,539)$ |  | $(759,405)$ |
| FINANCING ACTIVITIES |  |  |  |  |
| Issuance of Class A Common Stock |  | (300) |  | - |
| Repurchase of Class A Common Stock |  | $(25,000)$ |  | - |
| Repurchase of Class A Common Stock subject to repurchase |  | $(138,180)$ |  | - |
| Exercise of stock options |  | - |  | 23,799 |
| Net borrowings under line of credit |  | 406,837 |  | - |
| Payments of capital lease obligations |  | $(26,667)$ |  | $(50,688)$ |
| Net cash provided by (used in) financing activities |  | 216,690 |  | $(26,889)$ |
| Net decrease in cash and cash equivalents |  | $(183,840)$ |  | $(180,443)$ |
| Cash and cash equivalents at beginning of period |  | 420, 072 |  | 5,893,897 |
| Cash and cash equivalents at end of period | \$ | 236, 232 | \$ | 5,713,454 |

## FORENSIC TECHNOLOGIES INTERNATIONAL CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
MARCH 31, 1997

## 1. BASIS OF PRESENTATION

The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and Item 310(b) of Regulation S-B. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. For further information, refer to the consolidated financial statements and notes thereto included in the Company's annual report on Form $10-K S B$ for the year ended December 31, 1996.

In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three month period ended March 31, 1997 are not necessarily indicative of the results that may be expected for the year ended December 31, 1997.

On September 30, 1996 the Company acquired all of the outstanding common stock of Teklicon, Inc. ("Teklicon") in exchange for 415,000 shares of common stock. The acquisition was accounted for as a pooling of interests and, accordingly, the Company's financial statements have been restated for all periods prior to the merger to include the financial position, results of operations, and cash flows of Teklicon. The accompanying consolidated statements of operations, and cash flows for the three month period ending March 31, 1996 have been restated to reflect the acquisition of Teklicon.

## 2. OPTION GRANTS

On March 25, 1997, the Board of Directors approved the issuance of options to purchase 300,000 shares of Class A Common Stock to key employees. The exercise prices of the shares granted range from $\$ 6.00$ to $\$ 9.50$ per share, at or above the estimated fair market value of a share of Class A Common Stock at the date of grant, and the options vest ratably over a three year period.

FORENSIC TECHNOLOGIES INTERNATIONAL CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) MARCH 31, 1997 (CONTINUED)

## 3. EARNINGS PER SHARE

The following table summarizes the computations of earnings per share for the three month period ended March 31, 1997. This table should be read in conjunction with Note 2 to the 1996 audited financial statements.

| THREE MONTHS ENDED MARCH 31 |  |  |
| :---: | :---: | :---: |
| (UNAUDITED) |  |  |
| 2,011,131 |  | 4,519,478 |
| 199,417 139,442 |  |  |
| 2,210,548 |  | 4,658,920 |
| \$ 304,426 | \$ | 639,585 |
| ==============================  <br> \$ $0.14 ~ \$ ~$ 0.14 |  |  |
| 2,011,131 |  | 4,519,478 |
| 199,417 |  | 139,442 |
| 655,200 |  | - |
| 378,000 |  | - |
| 3,243,748 |  | 4,658,920 |
| \$ 304,426 | \$ | 639,585 |
| 21,420 |  | - |
| \$ 325,846 | \$ | 639,585 |
| \$ 0.10 | \$ | 0.14 |

In February 1997, the Financial Accounting Standards Board issued Statement No. 128, "Earnings Per Share", which is required to be adopted on December 31, 1997. At that time, the Company will be required to change the method currently used to compute earnings per share and to restate all prior periods. The impact of Statement 128 on the calculation of earnings per share is not expected to be material.

## MANAGEMENT'S DISCUSSION AND ANALYSIS OF <br> RESULTS OF OPERATIONS AND FINANCIAL CONDITION

Revenues for the first quarter ended March 31, 1997, increased 37.0\%, to \$9.5 million compared to the same period in 1996. This increase is primarily the result of revenues from visual communication services growing 96.6\% to \$4.7 million during the quarter, attributable to three factors: a resumption of casework following the December 1996, holiday hiatus; a historically high level of active trials during the period; and, the particular success of an integrated approach to the marketing of the Company's services. Trial consulting increased $5.1 \%$ during the quarter, due to continued demand for these services during the period; engineering revenues grew 5.6\%, attributable to increased sales by Teklicon, while other engineering services were generally flat compared to 1996.

Direct costs, as a percentage of revenue, were approximately the same during the first quarter of 1997 and 1996, as a result of managing the mix of internal and external resources to meet the demands for the Company's services. Selling, general and administrative expenses decreased as a percent of revenue as the fixed and semi-variable costs continued to benefit from larger increases in revenues. Interest expense decreased in the quarter due to no usage on the line of credit during 1997; borrowings under the line of credit during 1996 were repaid from funds received from the sale of Common Stock in May, 1996. Unused funds from such sale have been invested to increase interest income subsequent to May, 1996.

Cash flow provided by operations during the quarter, were offset by additional investments in office facilities and computer equipment. These investments assist the Company in providing enhanced services to its clients. The net decrease in cash was funded by the remaining balance of the net proceeds from the sale of the Company's stock in May, 1996. Such balance, approximately \$5.7 million, will be used for working capital and other general corporate purposes, including possible acquisitions.

3-MOS
DEC-31-1997
JAN-01-1997 MAR-31-1997

1
5,713,454
0
10,577, 077
406, 316
332,828
16,890,570
10,689, 464
5,926, 078
22,176,425
3,521,388
0
0
45,269
18,246,693
$22,176,425$
9,539,549
9,539,549
5,161, 672
8,511,216
0
0
19,971
1, 084, 042 444,457
639,585
0
639, 585
0.14
0.14

